Precision Quantomics joins BioTools Innovator 2026 accelerator

Precision Quantomics, a Spokane bioscience company focused on quantitative proteomics, has been selected for BioTools Innovator’s 2026 Accelerator Program. The move gives the company mentorship and industry access as it works to advance drug development tools and New Approach Methodologies.

Why it matters: - Precision Quantomics is trying to make drug development faster and more data-driven by giving researchers earlier biological insight. - The BioTools Innovator selection can help the Spokane company expand its reach with pharmaceutical partners and life science customers. - The company’s work also supports New Approach Methodologies, or NAMs, which are drawing more interest as alternatives and complements to traditional development workflows.

What happened: - Precision Quantomics announced its selection for the BioTools Innovator 2026 Accelerator Program on June 30, 2026. - BioTools Innovator chose the company for support that includes industry mentorship, strategic guidance and connections across the life sciences community. - Jim West, MS, associate director of BioTools Innovator, said the selection committee was drawn to the company’s technology, market adoption and integration within existing instrument workflows.

The details: - Precision Quantomics is a Spokane-based bioscience company focused on quantitative proteomics and translational drug development. - The company says its tools help researchers and pharmaceutical partners make more informed decisions across therapeutic development. - Its applications include drug discovery, drug development, NAMs, translational research, biomarker discovery and therapeutic evaluation. - Chandima Bandaranayaka, CEO of Precision Quantomics, said drug development remains complex and resource-intensive and needs better tools to generate actionable insights earlier in the process. - The company says it applies quantitative proteomics to provide deeper biological understanding and support more informed therapeutic development decisions. - Precision Quantomics also says its work helps researchers evaluate emerging approaches such as NAMs while generating quantitative data to improve confidence in development decisions. - The company has also received recent recognition and support from the Health Sciences & Services Authority of Spokane County to advance drug development innovation and help grow the region’s life sciences ecosystem. - Precision Quantomics develops quantitative proteomics solutions, biological reagents and data-driven in silico tools. - The company says these products improve the efficiency and accuracy of modern drug development. - More information is available on the company’s website.

Between the lines: - BioTools Innovator is signaling that it values not just new technology, but evidence of market traction. - The emphasis on a growing pharmaceutical customer base suggests Precision Quantomics is past the purely experimental stage and pushing toward wider adoption. - The mention of existing instrument workflows matters because tools that fit current lab systems are typically easier to deploy.

What's next: - Precision Quantomics will use the accelerator for mentorship, strategic guidance and broader industry connections. - The company is expected to continue scaling its technology and expanding its reach in quantitative proteomics and drug development. - BioTools Innovator’s backing could help the company deepen adoption among life science and pharmaceutical customers.

The bottom line: - Precision Quantomics is gaining accelerator support at a moment when drug development teams are looking for more quantitative, earlier-stage decision tools.